Hours instead of days

Today’s time-consuming diagnosis of sepsis leads to prolonged patient hospitalization, increased mortality, and an overuse of broad-spectrum antibiotics. Q-linea’s fully automated ASTar™ system cuts the diagnostic time for sepsis and deliver clinically-actionable results in hours instead of days.


Rapid AST directly from blood culture

ASTar™ is a fully automated, “load-and-go”, instrument for Antibiotic Susceptibility Testing (AST), giving a susceptibility profile within three to six hours directly from a positive blood culture. ASTar shortens time to result, enabling early use of antibiotics specifically targeting the disease causing pathogen.


Sepsis – a growing threat to public health

Sepsis is a global health problem, afflicting as many as 30 million people every year. Sepsis is a life-threatening condition, every hour that effective treatment is delayed may have a devastating effect. ASTar will shorten the time to correct antibiotic treatment with more than 24 hours.


  • Stabilization notice

    December 18, 2018
    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES Carnegie Investment Bank AB (publ) (”Carnegie”) notifies that stabilization measures have been undertaken in Q-linea AB (publ) (”Q-linea” or the “Company”) shares traded on Nasdaq Stockholm.
    Read more
  • Trading in Q-linea’s share commences tomorrow on Nasdaq Stockholm

    December 6, 2018
    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.
    Read more
  • Q-linea publishes prospectus for Initial Public Offering on Nasdaq

    November 23, 2018
    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.
    Read more

Do you want to know more? Subscribe to our mailing list!